The Ledger

435,000: that is how many people are about to lose their health insurer entirely, after a deal to save its Medicare Advantage business collapsed this week. Providence Health Plan, the insurance arm of the Renton, Washington based Providence health system, confirmed it will shut down its remaining insurance lines completely after talks with an unnamed national insurer to take over its Medicare Advantage business fell through “despite significant effort on all sides,” according to a company spokesperson. The closure affects more than 64,000 Medicare Advantage members, roughly 58,400 Medicaid enrollees and more than 260,000 people in commercial, ACA marketplace and employer group plans, on top of the individual and small group wind down Providence announced in May 2026; coverage continues without interruption through the end of 2026, and Providence says it will honor all contractual and regulatory obligations during the transition. The insurance division lost more than 100 million dollars in 2025 before narrowing that loss to 4 million dollars in the first half of 2026, even as the broader Providence health system posted 349 million dollars in net income over the same period, a split that shows the hospital side recovering while the health plan side still could not find a buyer. Confidence: High on the closure and the member counts, which Providence itself confirmed to reporters. Medium on the specific loss figures, which this run confirmed through financial trade press reporting rather than a Providence financial statement. Sources: Providence Health Plan transition statement, Providence Health Plan, Providence Health Plan to close completely after Medicare Advantage deal falls through, Healthcare Dive.

490 million dollars: that is the most a rare disease drugmaker will pay for a still unapproved pill, betting it can become the first oral treatment for a genetic bone disease. BioMarin Pharmaceutical agreed August 19, 2026 to acquire Alesta Therapeutics for 275 million dollars upfront plus up to 215 million dollars in development and regulatory milestones, gaining ALE1, an oral small molecule candidate for hypophosphatasia, a rare genetic bone disease currently in an early Phase 1/2a trial. Alesta will spin out all of its other assets to a separate company before the deal closes, and none of its employees will join BioMarin; the transaction, funded with cash on hand, is expected to close this quarter. Confidence: High. The deal terms come directly from BioMarin’s own investor relations release. Source: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, BioMarin Pharmaceutical investor relations.

870.6 million dollars: that is what a hospital operator just paid, in cash it borrowed, to own a virtual therapy platform outright. Universal Health Services completed its acquisition of Talkspace on August 17, 2026, paying 5.25 dollars per share in a debt financed deal that delivered approximately 870.6 million dollars in aggregate cash to Talkspace shareholders; the transaction was first announced March 9, 2026 and closed after receiving all required regulatory approvals. UHS, which operates acute care and behavioral health facilities nationwide, says pairing Talkspace’s virtual counseling and psychiatry network, which reaches more than 200 million Americans through insurance and benefit arrangements, with its own inpatient and outpatient behavioral health facilities creates an “end to end” behavioral health system that can refer patients between virtual and in person care. Confidence: High. The deal terms come directly from UHS’s own press release. Source: Universal Health Services, Inc. Completes Acquisition of Talkspace, Inc., Universal Health Services.

700 million dollars: that is roughly the size of the activist stake that got a hedge fund CEO a CVS board seat two years ago. Now he is gone, replaced by a JPMorgan data executive. CVS Health announced August 17, 2026 that Larry Robbins, chief executive of Glenview Capital Management, departed its board of directors effective August 13, 2026, with Teresa Heitsenrether, JPMorgan Chase’s chief data and analytics officer, set to join effective November 18, 2026. Robbins joined CVS’s board in November 2024 after Glenview built a roughly 700 million dollar stake and pushed for cost cuts and a leadership change; CVS has since replaced its chief executive and launched a multiyear plan to cut 2 billion dollars in costs. Confidence: High on the board changes, which come directly from CVS’s own release. Medium on what the swap signals about the state of Glenview’s campaign, since CVS did not characterize Robbins’s departure as the campaign’s end. Source: CVS Health Announces Board Changes, CVS Health investor relations.

1.5 percent: that is the median operating margin nonprofit hospitals posted in 2025, the best in Fitch’s dataset since before the pandemic, and Fitch says it might be as good as it gets. Fitch Ratings’ 2026 median ratios report, covering 222 rated nonprofit hospitals and health systems, found the median operating margin rose to 1.5 percent in 2025 from 1.1 percent in 2024, with 67 percent of providers posting positive margins, up from 64 percent in 2024 and roughly half in 2022; slower labor cost growth, with personnel expenses falling to 52.6 percent of operating revenue from 53.5 percent, drove much of the gain. Fitch warned that “fiscal 2025 may ultimately prove to be an operational peak for the sector before a new and more challenging chapter begins,” citing Medicaid funding reductions under the One Big Beautiful Bill Act that will pressure providers, especially Medicaid dependent and lower rated systems, starting in 2027; the agency’s outlook for 2026 calls for a median margin of 1 to 2 percent and roughly equal numbers of upgrades and downgrades. Confidence: High. The figures and quote come directly from Fitch’s own published report. Source: 2026 Median Ratios: Not-for-Profit Hospitals & Health Systems, Fitch Ratings.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Alesta Therapeutics	BioMarin Pharmaceutical	Biotech, rare disease therapeutics	Up to $490 million ($275 million upfront plus up to $215 million in milestones); announced August 19, 2026, expected to close this quarter	BioMarin to Acquire Alesta Therapeutics, BioMarin Pharmaceutical investor relations
Talkspace	Universal Health Services	Digital health, behavioral telehealth	Approximately $870.6 million aggregate cash, $5.25/share; deal closed August 17, 2026	Universal Health Services, Inc. Completes Acquisition of Talkspace, Inc., Universal Health Services
Healthcare IT Leaders, LLC	Kyndryl	Healthcare IT consulting and managed services	Undisclosed; announced August 10, 2026, expected to close in Kyndryl’s fiscal second quarter 2027	Kyndryl announces agreement to purchase Healthcare IT Leaders, LLC, Kyndryl

This run’s scan of PE Hub, Axios Pro Rata, FTC and DOJ merger actions and state transaction review dockets over the last 24 to 48 hours found the three transactions above; no new FTC or DOJ healthcare antitrust actions were spotted in this window.